ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy

ImCheck Therapeutics announced positive interim data from its Phase I/II EVICTION study evaluating ICT01, a γ9δ2 T-cell activator, in combination with...
Home/KnloSights/Clinical Trial Updates/ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy